FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes

Experimental Cell Research

Volumn 316, Issue 12, 2010, Pages 2008-2016

  Hafner, Christian ^a   Di Martino, Erica ^b   Pitt, Eva ^b   Stempfl, Thomas ^c   Tomlinson, Darren ^b   Hartmann, Arndt ^d   Landthaler, Michael ^a   Knowles, Margaret ^b   Vogt, Thomas ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c Center of Excellence for Fluorescent Bioanalytics (KFB)   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Apoptosis; Cell growth; FGFR3; Keratinocyte; Skin

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE 3;

APOPTOSIS; ARTICLE; CELL COUNT; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; DIMERIZATION; DISULFIDE BOND; DOWN REGULATION; EXPRESSION VECTOR; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSDUCTION; GROWTH RATE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; KERATINOCYTE; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SENESCENCE; SIGNAL TRANSDUCTION;

EID: 77953363228     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.04.021     Document Type: Article

References (43)

1. Ornitz D.M., Itoh N. Fibroblast growth factors. Genome Biol. 2001, 2. (REVIEWS3005).
2. L'Hote C.G., Knowles M.A. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp. Cell Res. 2005, 304:417-431.
3. Scotet E., Houssaint E. The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific. Biochim. Biophys. Acta 1995, 1264:238-242.
4. Meyers G.A., Orlow S.J., Munro I.R., Przylepa K.A., Jabs E.W. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat. Genet. 1995, 11:462-464.
5. Muenke M., Gripp K.W., McDonald-McGinn D.M., Gaudenz K., Whitaker L.A., Bartlett S.P., Markowitz R.I., Robin N.H., Nwokoro N., Mulvihill J.J., Losken H.W., Mulliken J.B., Guttmacher A.E., Wilroy R.S., Clarke L.A., Hollway G., Ades L.C., Haan E.A., Mulley J.C., Cohen M.M., Bellus G.A., Francomano C.A., Moloney D.M., Wall S.A., Wilkie A.O., Zackai E.H. A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am. J. Hum. Genet. 1997, 60:555-564.
6. Vajo Z., Francomano C.A., Wilkin D.J. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr. Rev. 2000, 21:23-39.
7. Baker K.M., Olson D.S., Harding C.O., Pauli R.M. Long-term survival in typical thanatophoric dysplasia type 1. Am. J. Med. Genet. 1997, 70:427-436.
8. Webster M.K., Donoghue D.J. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet. 1997, 13:178-182.
9. Chesi M., Nardini E., Brents L.A., Schrock E., Ried T., Kuehl W.M., Bergsagel P.L. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 1997, 16:260-264.
10. Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., Chopin D., Thiery J.P., Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 1999, 23:18-20.
11. Bernard-Pierrot I., Brams A., Dunois-Larde C., Caillault A., Diez de Medina S.G., Cappellen D., Graff G., Thiery J.P., Chopin D., Ricol D., Radvanyi F. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006, 27:740-747.
12. Qing J., Du X., Chen Y., Chan P., Li H., Wu P., Marsters S., Stawicki S., Tien J., Totpal K., Ross S., Stinson S., Dornan D., French D., Wang Q.R., Stephan J.P., Wu Y., Wiesmann C., Ashkenazi A. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J. Clin. Invest. 2009, 119:1216-1229.
13. Tomlinson D.C., Hurst C.D., Knowles M.A. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007, 26:5889-5899.
14. Logie A., Dunois-Larde C., Rosty C., Levrel O., Blanche M., Ribeiro A., Gasc J.M., Jorcano J., Werner S., Sastre-Garau X., Thiery J.P., Radvanyi F. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum. Mol. Genet. 2005, 14:1153-1160.
15. Hafner C., van Oers J.M., Vogt T., Landthaler M., Stoehr R., Blaszyk H., Hofstaedter F., Zwarthoff E.C., Hartmann A. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J. Clin. Invest. 2006, 116:2201-2207.
16. Hafner C., Stoehr R., van Oers J.M., Zwarthoff E.C., Hofstaedter F., Landthaler M., Hartmann A., Vogt T. FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo. Br. J. Dermatol. 2009, 160:546-551.
17. Naski M.C., Wang Q., Xu J., Ornitz D.M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat. Genet. 1996, 13:233-237.
18. d'Avis P.Y., Robertson S.C., Meyer A.N., Bardwell W.M., Webster M.K., Donoghue D.J. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ. 1998, 9:71-78.
19. Li E., You M., Hristova K. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. J. Mol. Biol. 2006, 356:600-612.
20. Monsonego-Ornan E., Adar R., Feferman T., Segev O., Yayon A. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol. Cell. Biol. 2000, 20:516-522.
21. Lievens P.M., Roncador A., Liboi E. K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2alpha and PLCgamma-independent pathways. J. Mol. Biol. 2006, 357:783-792.
22. Krejci P., Salazar L., Kashiwada T.A., Chlebova K., Salasova A., Thompson L.M., Bryja V., Kozubik A., Wilcox W.R. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PLoS One 2008, 3:e3961.
23. Hafner C., Vogt T., Hartmann A. FGFR3 mutations in benign skin tumors. Cell Cycle 2006, 5:2723-2728.
24. Tomlinson D.C., L'Hote C.G., Kennedy W., Pitt E., Knowles M.A. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res. 2005, 65:10441-10449.
25. Hafner C., Schmitz G., Meyer S., Bataille F., Hau P., Langmann T., Dietmaier W., Landthaler M., Vogt T. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin. Chem. 2004, 50:490-499.
26. Mandinova A., Kolev V., Neel V., Hu B., Stonely W., Lieb J., Wu X., Colli C., Han R., Pazin M., Ostano P., Dummer R., Brissette J.L., Dotto G.P. A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J. Clin. Invest. 2009, 119:3127-3137.
27. Sahni M., Ambrosetti D.C., Mansukhani A., Gertner R., Levy D., Basilico C. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 1999, 13:1361-1366.
28. Hafner C., Hartmann A., Real F.X., Hofstaedter F., Landthaler M., Vogt T. Spectrum of FGFR3 mutations in multiple intraindividual seborrheic keratoses. J. Invest. Dermatol. 2007, 127:1883-1885.
29. Hafner C., Hartmann A., van Oers J.M., Stoehr R., Zwarthoff E.C., Hofstaedter F., Landthaler M., Vogt T. FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization. Mod. Pathol. 2007, 20:895-903.
30. Hafner C., van Oers J.M., Hartmann A., Landthaler M., Stoehr R., Blaszyk H., Hofstaedter F., Zwarthoff E.C., Vogt T. High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J. Invest. Dermatol. 2006, 126:2404-2407.
31. Hafner C., Vogt T. Seborrheic keratosis. J. Dtsch. Dermatol. Ges. 2008, 6:664-677.
32. Hernandez S., Toll A., Baselga E., Ribe A., Azua-Romeo J., Pujol R.M., Real F.X. Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors. J. Invest. Dermatol. 2007, 127:1664-1666.
33. van Rhijn B.W., Montironi R., Zwarthoff E.C., Jobsis A.C., van der Kwast T.H. Frequent FGFR3 mutations in urothelial papilloma. J. Pathol. 2002, 198:245-251.
34. di Martino E., L'Hote Test G. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene 2009, 28:4306-4316.
35. Hafner C., Lopez-Knowles E., Luis N.M., Toll A., Baselga E., Fernandez-Casado A., Hernandez S., Ribe A., Mentzel T., Stoehr R., Hofstaedter F., Landthaler M., Vogt T., Pujol R.M., Hartmann A., Real F.X. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13450-13454.
36. Harada D., Yamanaka Y., Ueda K., Nishimura R., Morishima T., Seino Y., Tanaka H. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1. Bone 2007, 41:273-281.
37. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
38. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., Benguria A., Zaballos A., Flores J.M., Barbacid M., Beach D., Serrano M. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642.
39. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
40. Rothnagel J.A., Dominey A.M., Dempsey L.D., Longley M.A., Greenhalgh D.A., Gagne T.A., Huber M., Frenk E., Hohl D., Roop D.R. Mutations in the rod domains of keratins 1 and 10 in epidermolytic hyperkeratosis. Science 1992, 257:1128-1130.
41. Passos-Bueno M.R., Wilcox W.R., Jabs E.W., Sertie A.L., Alonso L.G., Kitoh H. Clinical spectrum of fibroblast growth factor receptor mutations. Hum. Mutat. 1999, 14:115-125.
42. Ornitz D.M., Marie P.J. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 2002, 16:1446-1465.
43. Krejci P., Salazar L., Goodridge H.S., Kashiwada T.A., Schibler M.J., Jelinkova P., Thompson L.M., Wilcox W.R. STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes. J. Cell Sci. 2008, 121:272-281.